Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Rockwell Medical, Inc. (NASDAQ:RMTI) Analyst Rating in Focus - Investor Newswire |
 |
 |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) shares have been given a 1.8 rating by analysts surveyed by Zacks Investment Research. Sell-side firms often use different terminology for their ratings so this scale provides a simple consensus number. The ratings are calculated on a 1 to 5 scale where 1 represents a Strong Buy and 5 a Strong Sell. When analysts were polled three months ago, the stock had an average rating of 1.8. Sell-Side brokerage firms have a price target of $16 on shares of Rockwell Medical, Inc. (NASDAQ:RMTI). This is based on analysts one year projections on the stock. The most bearish analyst outlook has a price target of $4, while the most aggressive firm sees the stock reaching $26 within the year. Earnings Glance Investors will be marking 2015-07-30 on their calendars as this is when Rockwell Medical, Inc. is slated to next issue their quarterly earnings. Analysts surveyed by Zacks are anticipating earnings of $-0.11 per share for the period closing on 2015-06-30. This is the Zacks consensus number based on 5 Wall Street analysts covering the equity. Looking ahead longer term, the Sell-Siders have tagged the stock with expected earnings of $88.7. This is the best estimate for both sales and earnings over the next 3-5 years, as calculated by Zacks. For the most recent quarter, Rockwell Medical, Inc. announced earnings per share of $-0.07 for the fiscal period ending on 2015-03-31. The actual number was $0.03 away from what analysts had expected, or a 30% surprise factor. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
